Drug Trial Radar · NCT07723833
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
152
Planned (sponsor's estimate)
Start
Jul 27, 2026
Primary completion
Nov 18, 2026
Study completion Nov 18, 2026
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jul 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to measure the pharmacokinetics (PK-how the body processes the study drug) of elecoglipron in healthy participants when taken by mouth as different formulations.
Conditions
- Healthy Participants
Interventions
Elecoglipron Reference Formulation Dose ADrug
Elecoglipron tablets will be administered orally.
Elecoglipron Test formulation 1 Dose ADrug
Elecoglipron tablets will be administered orally.
Elecoglipron Reference Formulation Dose BDrug
Elecoglipron tablets will be administered orally.
Elecoglipron Test formulation 1 Dose BDrug
Elecoglipron tablets will be administered orally.
Elecoglipron Test formulation 2 Dose ADrug
Elecoglipron tablets will be administered orally.
Elecoglipron Test formulation 2 Dose BDrug
Elecoglipron tablets will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum observed drug concentration (Cmax)Time frame: At pre-defined intervals from Day 1 to Day 15
- Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast)Time frame: At pre-defined intervals from Day 1 to Day 15
- Area under concentration-time curve from time 0 to infinity (AUCinf)Time frame: At pre-defined intervals from Day 1 to Day 15
- Time to reach maximum observed concentration (tmax)Time frame: At pre-defined intervals from Day 1 to Day 15
- Terminal elimination rate constant (λz)Time frame: At pre-defined intervals from Day 1 to Day 15
- Terminal elimination half-life (t1/2λz)Time frame: At pre-defined intervals from Day 1 to Day 15
- Apparent total body clearance (CL/F)Time frame: At pre-defined intervals from Day 1 to Day 15
- Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: At pre-defined intervals from Day 1 to Day 15
- Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUCinf (R AUCinf)Time frame: At pre-defined intervals from Day 1 to Day 15
- Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on AUClast (R AUClast)Time frame: At pre-defined intervals from Day 1 to Day 15
- Ratio of elecoglipron (test formulation) to elecoglipron (reference formulation) based on Cmax (R Cmax)Time frame: At pre-defined intervals from Day 1 to Day 15
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Glendale, California · Recruiting
Research Site
Brooklyn, Maryland · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.